Celldex Therapeutics (CLDX) Equity Average (2016 - 2025)
Historic Equity Average for Celldex Therapeutics (CLDX) over the last 15 years, with Q3 2025 value amounting to $626.9 million.
- Celldex Therapeutics' Equity Average fell 2161.81% to $626.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $626.9 million, marking a year-over-year decrease of 2161.81%. This contributed to the annual value of $588.1 million for FY2024, which is 5570.76% up from last year.
- Per Celldex Therapeutics' latest filing, its Equity Average stood at $626.9 million for Q3 2025, which was down 2161.81% from $679.2 million recorded in Q2 2025.
- Celldex Therapeutics' 5-year Equity Average high stood at $826.1 million for Q2 2024, and its period low was $188.2 million during Q2 2021.
- For the 5-year period, Celldex Therapeutics' Equity Average averaged around $466.9 million, with its median value being $381.6 million (2022).
- As far as peak fluctuations go, Celldex Therapeutics' Equity Average tumbled by 2621.42% in 2023, and later soared by 20511.18% in 2024.
- Quarter analysis of 5 years shows Celldex Therapeutics' Equity Average stood at $428.1 million in 2021, then fell by 21.56% to $335.8 million in 2022, then rose by 0.64% to $337.9 million in 2023, then skyrocketed by 126.8% to $766.5 million in 2024, then fell by 18.21% to $626.9 million in 2025.
- Its last three reported values are $626.9 million in Q3 2025, $679.2 million for Q2 2025, and $725.0 million during Q1 2025.